GlassScriptPhysician profile
David C Oliver
NPI 1891741013
$3,044.35
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,394 · 2020: $445 · 2021: $595 · 2022: $521 · 2023: $88.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $88.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $88.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $312.89 | 2019-2023 | |
| Amgen INC. | $286.39 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $276.82 | 2019-2022 | |
| Abbott Laboratories | $211.56 | 2019-2023 | Cardiomems |
| Sanofi-Aventis U.S. LLC | $186.87 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $141.07 | 2019-2020 | |
| Edwards Lifesciences Corporation | $137.77 | 2019 | |
| Amarin Pharma, INC. | $133.02 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $120.47 | 2019-2020 | |
| Medtronic, INC. | $116.53 | 2022-2023 | Corevalve Evolut R |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.78 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $105.65 | 2019-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $88.68 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $79.23 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.17 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $72.66 | 2019 | |
| Merck Sharp & Dohme LLC | $68.18 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $52.78 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $47.63 | 2019 | |
| Esperion Therapeutics, INC. | $46.02 | 2021 | |
| Pfizer INC. | $38.02 | 2019 | |
| Gilead Sciences, INC. | $35.51 | 2019 | |
| Novo Nordisk INC | $33.65 | 2021-2022 | |
| Daiichi Sankyo INC. | $32.19 | 2021 | |
| Braemar Manufacturing, LLC | $29.09 | 2019 | |
| Portola Pharmaceuticals, LLC | $24.00 | 2020 | |
| Cvrx, INC. | $23.57 | 2022-2023 | Barostim Neo System |
| Genzyme Corporation | $19.07 | 2019 | |
| Medtronic Vascular, INC. | $17.19 | 2019 | |
| Biotronik INC. | $14.67 | 2019 | |
| G Medical Diagnostic Services, INC. | $14.67 | 2022 | |
| Vifor Pharma, INC. | $14.61 | 2019 | |
| Irhythm Technologies, INC. | $14.48 | 2022 | |
| Cook Medical LLC | $14.09 | 2021 | |
| Lemaitre Vascular, INC. | $13.65 | 2019 | |
| Allergan, INC. | $13.18 | 2019 | |
| Astellas Pharma US INC | $13.04 | 2020 | |
| Lundbeck LLC | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.